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Abstract
Background: Niemann-Pick Type C disease (NPC), is an autosomal recessive neurovisceral disorder of lipid
metabolism. One characteristic feature of NPC is a vertical supranuclear gaze palsy particularly affecting saccades.
However, horizontal saccades are also impaired and as a consequence a parameter related to horizontal peak
saccadic velocity was used as an outcome measure in the clinical trial of miglustat, the first drug approved in several
jurisdictions for the treatment of NPC. As NPC-related neuropathology is widespread in the brain we examined a wider
range of horizontal saccade parameters and to determine whether these showed treatment-related improvement and,
if so, if this was maintained over time.
Methods: Nine adult NPC patients participated in the study; 8 were treated with miglustat for periods between 33 and
61 months. Data were available for 2 patients before their treatment commenced and 1 patient was untreated. Tasks
included reflexive saccades, antisaccades and self-paced saccades, with eye movements recorded by an infrared
reflectance eye tracker. Parameters analysed were reflexive saccade gain and latency, asymptotic peak saccadic velocity,
HSEM-α (the slope of the peak duration-amplitude regression line), antisaccade error percentage, self-paced saccade
count and time between refixations on the self-paced task. Data were analysed by plotting the change from baseline
as a proportion of the baseline value at each test time and, where multiple data values were available at each session,
by linear mixed effects (LME) analysis.
Results: Examination of change plots suggested some modest sustained improvement in gain, no consistent
changes in asymptotic peak velocity or HSEM-α, deterioration in the already poor antisaccade error rate and sustained
improvement in self-paced saccade rate. LME analysis showed statistically significant improvement in gain and the
interval between self-paced saccades, with differences over time between treated and untreated patients.
Conclusions: Both qualitative examination of change scores and statistical evaluation with LME analysis support the
idea that some saccadic parameters are robust indicators of efficacy, and that the variability observed across measures
may indicate locally different effects of neurodegeneration and of drug actions.
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Background
Niemann-Pick Type C disease (NPC) is an autosomal re-
cessive neurovisceral disorder of glycosphingolipid metab-
olism arising from mutations in the NPC1 or NPC2 genes
[1, 2]. While no symptom in isolation is pathognomonic
for NPC, the presence of a vertical supranuclear gaze palsy
(VSGP), particularly of saccadic eye movements, is
strongly indicative of NPC when seen in the presence of
splenomegaly, ataxia, psychosis and/or cognitive decline
[3]. In late-onset patients whose presenting symptom may
be schizophrenia-like psychosis or ataxia associated with
cognitive decline, evaluation of the range of gaze with
smooth eye movements rather than by eliciting saccades
can delay proper diagnosis for years [2].
The high prevalence of VSGP in NPC would seem to
make it a useful marker for assessing the efficacy of
treatment, particularly as ocular motor pathways are
relatively well understood. However, by the time diagno-
sis is confirmed, vertical saccades are often virtually ab-
sent. While essentially normal in the earlier stages of the
disease [4, 5], definite abnormalities can be identified in
horizontal saccadic function as the disease progresses.
Their state of being impaired, but not absent, led to the
use of the slope of the peak duration versus amplitude
regression line, termed horizontal saccadic eye move-
ment alpha (HSEM-α) [6] as one of the principal out-
come measures in the clinical trial of miglustat, the first
medication approved in a range of jurisdictions for the
treatment of NPC [7, 8]. Peak duration is defined as the
amplitude of a saccade divided by its peak velocity and
HSEM-α corresponds to the inverse of the asymptote
Vmax of an exponential curve fitted directly to peak vel-
ocity versus amplitude plots [6], sometimes termed the
“main sequence.” Two reports arising from this clinical
trial have reported that HSEM-α and other improvements
seen; e.g., ambulation and swallowing, at 12 months were
maintained at 24 months [7, 9]. This implies that neurons
responsible for generating the burst of innervation which
determines peak saccadic velocity—excitatory burst
neurons in the paramedian pontine reticular formation
(PPRF)—benefitted from miglustat treatment.
However, peak saccadic velocity is far from the only
saccadic parameter which can be measured and whose
neural correlates are known. For saccades made in re-
sponse to the sudden appearance of a target, saccadic ac-
curacy or gain (saccade amplitude divided by stimulus
displacement) depends upon the integrity of both the
parietal eye fields [10] and cerebellar vermis [11]. Sac-
cadic reaction time or latency can readily be measured
for these saccades as well. This is often prolonged in
neurodegenerative disorders such as Alzheimer’s disease
[12, 13] but less so in progressive supranuclear palsy
[14] or frontotemporal dementia [15]. We previously re-
ported latency as intact in NPC [16].
In addition to reflexive or prosaccades made to sud-
denly appearing stimuli, saccades can also be made
under volitional control to consciously chosen locations.
One can also consciously suppress saccades which other-
wise would be elicited by stimulus appearance (as on the
antisaccade task). Saccadic tasks which draw upon these
capabilities can be used to assess elements of cognition
and the integrity of areas of frontal cortex and projec-
tions from there via the basal ganglia to the brainstem.
Since NPC has been associated with atrophy of the
frontal lobes [17], assessment of frontally mediated sac-
cade tasks could provide additional information about
NPC-related declines in these “higher-order” functions
and about the integrity of their underlying neural sub-
strates. We recently reported on the performance of a
group of nine adult NPC patients and ten age-matched
controls on both reflexive and volitional saccade tasks
[16]. Several of the parameters (antisaccade error rate,
self-paced saccade generation, reflexive saccade gain)
were better discriminators between NPC and control
groups than HSEM-α. What was not examined in this
initial study was whether these measures would show
improvement with miglustat treatment similar to that
seen in HSEM-α and whether any treatment effect
would be sustained. This is the subject of the present
report.
Methods
Nine patients (5 male, 4 female, mean age 32.4 ± 9.71 years)
recruited from the Royal Melbourne Hospital were assessed
between 2006 and 2013. Intervals between assessments var-
ied between 7 and 12 months. In addition to the recent
baseline study [16] some other findings in these patients
have been reported elsewhere [18, 19]. All patients provided
written informed consent and the study was approved by
the Melbourne Health human research and ethics commit-
tee (HREC 2005.198). Diagnosis was confirmed with bio-
chemical analysis of cultured fibroblasts, using cholesterol
esterification rate and percentage of cells staining abnor-
mally for perinuclear cholesterol. In all but one patient,
diagnosis was also confirmed with mutations on the NPC1
gene All patients received 200 mg tds of miglustat except
for #9, who received 100 mg tds and #5, who was untreated
throughout. Patients #1 and #2 both were recorded twice
before the onset of medication. Iturriaga disease severity
scale ratings for the patients at their entry to the study are
found in Table 1.
As in our earlier studies [16, 18], horizontal eye move-
ments were recorded with a Microguide 1000 infrared
limbus tracker and digitised along with a target position
signal at 1000 Hz. The system is linear to at least 15 deg
and has 0.1 deg sensitivity. Targets were green LEDs on
an arc positioned 1.6 m from the subject. Task order
was fixed as given below, to ensure that the task most
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dependent on good calibration and alertness was run first.
Tasks used and the parameters assessed for each are as
follows: Prosaccades: Targets jumped pseudo-randomly to
the left and right of fixation so that 60 jumps between 5
and 30° were presented. Analyses of each saccade included
peak velocity, gain and latency. Saccade peak velocity was
plotted against saccade amplitude and fitted via nonlinear
regression with the curve V = Vmax(1 – e-amp/k), where
Vmax is the asymptotic peak velocity and V and amp are
the peak velocity and amplitude of each individual sac-
cade. HSEM-α, the slope of the regression line fitted to a
plot of peak duration versus amplitude [6], was also calcu-
lated. Antisaccades: 39 targets were presented pseudo-
randomly at ±5 and 10°. Subjects were instructed to not
look at the target but instead to a location at the same dis-
tance but in the opposite direction. Practice trials with
verbal feedback were given until subjects made at least
one correct response, to indicate that they understood the
task. Analysis was of the percentage of trials on which an
error was made. Self-paced saccades: Targets at ±10° were
illuminated and subjects instructed to look back and forth
between them as rapidly as possible Subjects were verbally
encouraged to keep moving during the trial, to minimise
the effects of fatigue or inattention. The number of sac-
cades completed in 30 s was tallied. For the subsequent
linear mixed effects analysis inter-saccadic interval was
also calculated, to allow for trial-by-trial data to be used
for this analysis.
Analyses
Data are first shown not in raw form at each time point
but as the change from baseline as a proportion of the
baseline value. What constitutes improvement or decline
depends upon the parameter shown; that is, for self-
paced saccade rate, Vmax and gain, an increase from
baseline is an improvement and is indicated by data
above the horizontal axis. For HSEM-α and antisaccade
error rate, a decline in the parameter value is an im-
provement and is indicated by data below the axis. This
was done for the all parameters, as seen in Fig. 1a–d. Pa-
tients 1 and 2 were tested before the baseline session;
hence, they also have data points before time zero and
these sessions and the baseline sessions are represented as
untreated data in the linear mixed effects analyses dis-
cussed below. The data from 5 and the untreated sessions
for 1 and 2 thus constitute the control data in this study.
Quantitative analysis was difficult in a dataset such as
this. Patient test-retest intervals varied, not all patients
could generate data for all tasks at all times, and the
number of repeat visits varied across patients. These
limitations precluded the use of repeated measures or
mixed analyses of variance. However, an alternative ap-
proach which makes maximal use of the data available,
linear mixed-effects modelling, was utilised.
Linear mixed-effect (LME) modelling techniques have
garnered increasing use, particularly in the field of psy-
cholinguistics (e.g., [20]). While several papers have ad-
dressed the advantages of using such a statistical
approach over the more traditional analysis of variance
(ANOVA) techniques (e.g., [21–23]), there are two main
reasons this approach was utilised. First, LME models
allow the inclusion of random factors. Here, the number
of participants is low, and therefore the LME model con-
siders all of the datapoints for each participant, and con-
trols for the variance between subjects. This gives the
analysis more statistical power, and greater sensitivity,
than an ANOVA - whereby each participant’s data from
each session would have to be condensed to a single cell
average. Correspondingly, the second reason for the
present use is that LME models can cope well with miss-
ing data, as not all participants here have data for the
same time points (given that not all sessions were evenly
spaced). The models presented here examine the change
in factors across time (reported in months), controlling
for the baseline variance in performance of our partici-
pants. Analysis was conducted using the lme4 [24] pack-
ages in R (version 2.12.0; R Development Core Team,
2010). Data were plotted using the ggplot package [25].
We show individual level data from all participants, as
well as presenting model data (Coefficient, SE, t and p
values) from separate LME models for treated, untreated
(1 patient and 2 patient’s pre-treatment visits) groups, as
well as interactions.
Results
Plots of the change scores are shown in Fig. 1 —as noted
above, for gain, Vmax and self-paced saccade rate, posi-
tive values are improvements from baseline, while for
HSEM-α, latency and antisaccade error rate negative
values denote improvement.
For five subjects changes in gain were positive, albeit
sometimes by a small amount. Only two subjects showed
improvement in Vmax and the related HSEM-α and three
Table 1 Iturriaga severity rating for patients at the time of their
entry into the study
Patient Illness scale at baseline
1 5
2 12
3 7
4 5
5 11
6 9
7 6
8 5
9 4
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subjects’ latency decreased; clearly, however, the data in
Fig. 1a to d show significant between-session variability.
Figure 2a and b show the change values for the two
volitional measures.
Antisaccade performance in our patients was poor at
baseline and generally became even worse, as evidenced
by the large positive change values for most subjects. In
contrast, there was a largely sustained improvement in
five of the eight treated patients’ self-paced saccade per-
formance; that is, their change scores were positive dur-
ing their time of treatment, meaning that they were
making more self-paced saccades in 30 s. Again, the data
vary considerably between sessions.
LME models
Inter-saccadic interval, self-paced saccade task
There was a significant interaction between time and the
treatment group on ISI (p < .001; Fig. 3). Patients in the
treatment group showed a small, but significant decrease
in ISI (i.e., a higher rate of self-paced saccade generation)
across time (β =–0.001, SE = 0.0003, t =–4.334, p < .001).
In contrast patients in the untreated group showed a
significant increase in ISI (i.e., a lower rate of self-paced
saccade generation) across time (β = 0.026, SE = 0.004,
t = 7.258, p < .001).
Gain
There was a significant interaction between time and
the treatment group on the saccadic gain scores (p < .001;
Fig. 4). Patients in the treatment group showed a
significant increase in gain across time (β = 0.001, SE =
0.0003, t = 2.08, p = .037). Again, patients in the untreated
group showed a different trend with a significant
decrease in gain across time (β =–0.004, SE = 0.001, t =–4.5,
p < .001).
Fig. 1 Change scores for (a) gain, (b) HSEM-α, (c) Vmax and (d) latency
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Latency
There was no significant interaction between time and the
treatment group on the saccadic latencies (p > .05; Fig. 5).
Patients in the treatment group showed a very small sig-
nificant increase in latency across time (β =–3.010e–04,
SE = 7.011e-05, t =–4.29, p = .04), however, the latency of
patients in the untreated group did not change across time
(p > .05).
We previously reported that baseline disease severity
correlated with a number of ocular motor parameters
[16]. The values of this assessment over time are
shown in Fig. 6.
Discussion
This report demonstrates the difficulties inherent in
conducting a longitudinal treatment study in a rare,
progressive and eventually fatal condition. However,
even given these limitations it is the most extensive
longitudinal study of saccadic eye movement function
in NPC to date. The results are broadly consistent with
Abel et al. [16], where prosaccade gain, self-paced sac-
cade rate and antisaccade error rate were the best dis-
criminators between patients and controls. In our
previous study antisaccade performance was already at
close to floor level and in this study we observed that, if
anything, it deteriorated further. Since NPC can lead to
frontal lobe atrophy [26], presumably the frontal lobe
structures essential for reflexive saccade inhibition were
already too extensively damaged at baseline to allow for
any meaningful treatment response, in the same way
that vertical saccades were already essentially absent in
our patients upon entry to the study. The marked failure
to suppress unwanted reflexive saccades has a behav-
ioural counterpart in the early presentation of disinhib-
ition in the context of other disturbances of executive
function [3].
Fig. 3 Individual patient ISIs across time, indicated in months since treatment onset. In this and the following two figures, plots with red triangles
are treated patients, blue triangles are reported in months since first visit of the untreated patient (UT5) and the two patients recorded before
miglustat intervention (UT1 and UT2). The grey lines are the treated and untreated model fits, with intercept varying across participant). The black
lines are individually fit regression models with blue shaded ± SE (allowing comparison of individual performance to the overall LME model fit
across all participants in that group). Patient numbering is as in Figs. 1 and 2
Fig. 2 Change scores for (a) antisaccade error rate and (b) self-paced saccade count
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In contrast, it is of interest that self-paced saccades,
mediated by the frontal eye fields [27] qualitatively
showed sustained improvement in the change plot and
this was borne out quantitatively in the LME analysis by
showing a significant decrease in intersaccadic interval
over time in treated patients and a significant ISI in-
crease in the untreated ones. This task is more readily
understood and executed by cognitively impaired pa-
tients than is the more complex antisaccade task and its
discrimination between controls and NPC patients and
its apparent improvement with treatment suggest that it
could be a useful addition to future treatment trials.
The measures derived from prosaccades showed less ro-
bust results than did self-paced saccades. The parameter
used in the miglustat clinical trial [8], HSEM-α, showed
improvement in some patients (i.e., lower values) and
deterioration in others (i.e., higher values). The same was
seen for Vmax, which is effectively the inverse of HSEM-α.
Neither of these parameters, being derived from curve-fits
to all data collected for a given session, could be
quantitatively analysed with LME analysis. The reflexive
parameters which could be addressed statistically were
gain and latency. The latter measure showed no differences
between controls and patients in our baseline study [16]
but with LME analysis showed a very small but significant
improvement over time. This may have been driven by pa-
tients 6 and 9, whose initially abnormally long latencies at
baseline (compared to the normal range) normalised in
subsequent trials. The preservation of intact horizontal
saccadic latency in NPC [16] renders it of little use as a
possible marker for treatment response or progression.
Gain, the remaining prosaccade parameter, does show
more potential as a treatment marker. It was the only sig-
nificant prosaccade discriminator between groups in our
baseline study and qualitatively in the change plot (Fig. 3a)
most data fell above the abscissa, suggesting improvement.
This was borne out in the LME analysis, wherein for the
NPC group there was a slight but significant improvement
in gain over time, while a decrement was seen over time
for the untreated subjects.
Fig. 4 Individual patient gains across time
Fig. 5 Individual patient latencies across time
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Clearly this study has a range of limitations: small sample
size, different levels of disease severity at intake, the difficul-
ties in maintaining recording quality in a significantly im-
paired population and variations in test-retest frequency
and timing. However, even in this small group we are able
to quantitatively demonstrate in some parameters (e.g., self-
paced saccade generation and prosaccade gain) an overall
improvement with treatment using LME modelling. The
LME models were sensitive enough to detect small im-
provements in these parameters, and differentiate between
treated and untreated patients, particularly for ISI (see
Fig. 3) where a clear increase was seen in patients during
untreated phases compared to a relatively stable (and a
slight decrease) in ISI was observed in patients treated with
miglustat. Other measures could only be evaluated qualita-
tively and either appeared to show no strong trend towards
either improvement or decline; performance on the antisac-
cade task, appeared to deteriorate even further from the ini-
tially poor baseline.
Conclusions
As new treatments are proposed and simpler diagnostics
become available for NPC, inclusion of measures such as
these may be useful objective, quantitative indicators of
treatment efficacy in a number of widely divergent brain
regions. Indeed, if diagnosis became possible earlier in the
disease course, even measures such as vertical saccade
performance or antisaccade error rate could be assessed
before the loss of their neural substrates rendered them
insensitive. In our cohort of adult-onset NPC patients, the
changes seen in these frontal and brainstem measures of
ocular-motor function support the assertion that miglustat
treatment for NPC does have a positive effect on multiple
regions in the CNS.
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